Assuntos
Transplante de Células/normas , Transplante de Órgãos/normas , Doadores de Tecidos/provisão & distribuição , Transplante de Tecidos/normas , Organização Mundial da Saúde , Transplante de Células/ética , Transplante de Células/legislação & jurisprudência , Regulamentação Governamental , Guias como Assunto , Política de Saúde , Humanos , Cooperação Internacional , Doadores Vivos/provisão & distribuição , Transplante de Órgãos/ética , Transplante de Órgãos/legislação & jurisprudência , Objetivos Organizacionais , Desenvolvimento de Programas , Doadores de Tecidos/ética , Doadores de Tecidos/legislação & jurisprudência , Transplante de Tecidos/ética , Transplante de Tecidos/legislação & jurisprudênciaRESUMO
Once pig organs can be transplanted into humans, transplantation will move into a new era. There will be unlimited access to undamaged organs, and cells for transplantation and, eventually, donation from deceased or live human beings will become obsolete. Furthermore, it will be possible to alleviate graft rejection, at least in part, by genetic modification of the source animal. Currently, there are three major obstacles to performing transplantations from pig to man: a powerful immune barrier, a potential risk of transmitting microorganisms, particularly endogenous retrovirus, and ethical issues related to the future recipients and to society at large. This article will first discuss the ongoing work with regards to overcoming the current obstacles. Also, the many potential advantages of using pig organs will be discussed in some detail. Furthermore, lessons learned from attempts at transplanting porcine cells to patients will be reviewed.
Assuntos
Transplante de Células/métodos , Transplante de Órgãos/métodos , Transplante Heterólogo/métodos , Animais , Animais Geneticamente Modificados , Transplante de Células/efeitos adversos , Transplante de Células/tendências , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/imunologia , Humanos , Transplante de Órgãos/efeitos adversos , Transplante de Órgãos/tendências , Suínos , Doenças dos Suínos/microbiologia , Doenças dos Suínos/transmissão , Doenças dos Suínos/virologia , Imunologia de Transplantes , Transplante Heterólogo/ética , Transplante Heterólogo/tendênciasRESUMO
BACKGROUND: Pig islets constitute a possible resolution to the shortage of human islets for transplantation. After intraportal infusion of porcine islets in primates, many islets are lost through what has been termed the instant blood-mediated inflammatory reaction (IBMIR). We report on our experience with IBMIR. METHODS: Ten monkeys underwent intraportal porcine islet transplantation. Immunosuppressive therapy was with conventional agents (n=3) or based on costimulation blockade (n=7). Treatment specific for IBMIR was administered in eight monkeys; two additional monkeys received no such therapy (group 1). Cobra venom factor completely inhibited complement activity in four (group 2) and dextran sulfate provided anticoagulation in four (group 3). Islet graft function was monitored by following blood glucose, insulin requirement, and porcine C-peptide values. RESULTS: In monkeys that received neither cobra venom factor nor dextran sulfate (group 1), there was rapid destruction of islets indicated by severe hypoglycemia and the need for dextrose infusion; C-peptide levels were initially low and further reduction occurred within the first five days. In both groups 2 and 3, there was significantly less destruction of islets and some reversal of diabetes. However, when 40,000 IEQ/kg were infused, normoglycemia was lost within five days, but when 80,000 IEQ/kg were infused in one case, normoglycemia was more persistent. We observed that even when C-peptide levels were in the normal range for healthy nondiabetic pigs, these were not sufficient to maintain normoglycemia in the monkeys. CONCLUSIONS: Although pretransplantation complement depletion or anticoagulation reduces porcine islet xenograft loss significantly, neither alone is sufficient to prevent IBMIR.
Assuntos
Rejeição de Enxerto/imunologia , Transplante das Ilhotas Pancreáticas/imunologia , Macaca fascicularis/imunologia , Suínos , Animais , Anticoagulantes/farmacologia , Glicemia/metabolismo , Peptídeo C/sangue , Ensaio de Atividade Hemolítica de Complemento , Feminino , Seguimentos , Rejeição de Enxerto/prevenção & controle , Imunossupressores/farmacologia , Insulina/sangue , Masculino , Fatores de Tempo , Transplante Heterólogo/imunologiaRESUMO
Once pig organs can be transplanted into humans, transplantation will move into a new era. There will be unlimited access to undamaged organs and cells for transplantation and, eventually, donation from deceased or live human beings will become obsolete. Furthermore, it will be possible to alleviate graft rejection, at least in part, by genetic modification of the source animal. Currently, there are three major obstacles to performing transplantations from pig to man: 1) a powerful immune barrier, 2) a potential risk of transmitting microorganisms, particularly endogenous retrovirus and 3) ethical issues related to the future recipients and to society at large.This article will first discuss ongoing work with regards to overcoming the current obstacles. Then, the many potential advantages of using pig organs will be listed. Next, the criteria for selecting the first patients for transplantation with pig organs, will be briefly discussed. Finally, some promising observations made in the context of early attempts at transplanting porcine cells to patients, will be mentioned.
Assuntos
Distinções e Prêmios , Transplante/história , Boston , História do Século XX , Sociedades Médicas , SuéciaRESUMO
BACKGROUND: The authors' aim was to evaluate the efficacy of immunosuppression with monoclonal anti-CD40 ligand antibodies (aCD40L) or nonspecific polyclonal intravenous immunoglobulin (IVIG) in the pig-to-rat islet xenotransplantation model. METHODS: Fetal porcine islet-like cell clusters were transplanted under the kidney capsule of nondiabetic rats. All antibodies were administered alone or in combination with cyclosporine A (CsA). In addition, some animals were administered antibodies plus tacrolimus (TAC) or sirolimus (SIR). Twelve days after transplantation, islet xenograft survival and rejection were evaluated using immunohistochemistry. RESULTS: aCD40L plus CsA had a pronounced inhibitory effect on islet xenograft rejection for up to 12 days after transplantation. Unexpectedly, treatment with a monoclonal control antibody (anti-keyhole limpet hemocyanin [aKLH]) plus CsA had a similar inhibitory effect. Furthermore, a similar inhibition of islet xenograft rejection was observed also in animals administered IVIG plus CsA. Monotherapy with aCD40L, aKLH, IVIG, or CsA had no effect on the rejection process. Also, when aCD40L or aKLH was administered together with TAC, islet xenograft rejection was inhibited. There was no marked difference compared with rats treated with aCD40L or aKLH and CsA. Immunosuppression with aCD40L or aKLH in combination with SIR also inhibited pig-to-rat islet xenograft rejection, but the protective effect was not as pronounced. CONCLUSIONS: Immunosuppression with high doses of antibodies, monoclonal or polyclonal, in combination with CsA or TAC inhibits pig-to-rat islet xenograft rejection. No specific effect of co-stimulatory blockade with aCD40L could be observed. Instead, the results indicate a nonspecific immunosuppressive effect of high doses of antibodies in this model.
Assuntos
Anticorpos Monoclonais/uso terapêutico , Ligante de CD40/imunologia , Transplante de Tecido Fetal/imunologia , Imunoglobulinas Intravenosas/uso terapêutico , Imunossupressores/uso terapêutico , Transplante das Ilhotas Pancreáticas/imunologia , Transplante Heterólogo/imunologia , Animais , Ciclosporina/uso terapêutico , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto/imunologia , Imuno-Histoquímica , Masculino , Ratos , Ratos Endogâmicos Lew , Suínos , Tacrolimo/uso terapêuticoAssuntos
Transplante de Órgãos/estatística & dados numéricos , Obtenção de Tecidos e Órgãos/organização & administração , Animais , Saúde Global , Humanos , Consentimento Livre e Esclarecido , Doadores Vivos , Pobreza , Segurança , Obtenção de Tecidos e Órgãos/ética , Obtenção de Tecidos e Órgãos/normas , Transplante Heterólogo/ética , Organização Mundial da SaúdeRESUMO
BACKGROUND: The aim of this study was to investigate whether transmission of porcine endogenous retrovirus (PERV) occurs in a model of diabetes reversal by the xenotransplantation of adult porcine islets (APIs) into immunoincompetent diabetic rodents. METHODS: Black-6 nu/nu mice and Lewis rats were immunosuppressed with cyclosporin A (CsA) and FTY 720, and rendered diabetic with streptozotocin. Purified APIs were transplanted into the renal subcapsular space; 5,000 islet equivalents (IEQs) were used in the nude mice (n = 4) and 40,000 IEQs in the rats (n = 4). The nude mice were sacrificed at 75 days after transplantation. In order to confirm chronic xenograft function, the graft-bearing kidney was removed prior to sacrifice. The rats were followed until xenograft rejection, at which time they were sacrificed. Immediately after sacrifice, tissue samples (liver, spleen, and small intestine) were taken for analysis. Quantitative polymerase chain reaction (PCR) was used to assess evidence of PERV transmission, and porcine cell chimerism. RESULTS: All animals became normoglycemic within 48 h of transplantation. The nude mice remained normoglycemic during the 75-day study period, with removal of the graft-bearing kidney resulting in prompt hyperglycemia. The rats remained normoglycemic until xenograft rejection, which occurred at 66 +/- 28 days. Despite the evidence of porcine cell microchimerism in recipients, real-time PCR detected no evidence of PERV transmission in any of the tissue specimens tested. CONCLUSIONS: There was no evidence of PERV transmission following transplantation of pig islets into diabetic nude mice and immunosuppressed rats.
Assuntos
Diabetes Mellitus/cirurgia , Retrovirus Endógenos/genética , Hospedeiro Imunocomprometido/imunologia , Transplante das Ilhotas Pancreáticas , Suínos/genética , Suínos/virologia , Transplante Heterólogo , Envelhecimento/fisiologia , Animais , Separação Celular , Quimerismo , RNA Polimerases Dirigidas por DNA/genética , Retrovirus Endógenos/isolamento & purificação , Masculino , Camundongos , Camundongos Nus , Ratos , Infecções por Retroviridae/veterinária , Infecções por Retroviridae/virologia , TransplanteRESUMO
One of the main obstacles to successful intraportal islet transplantation is the instant blood-mediated inflammatory reaction (IBMIR) elicited by the isolated islets when exposed to fresh human blood. In the present study, we investigated whether intraportal transplantation of pig islets into diabetic athymic mice could be used as a small animal model to study xenogeneic IBMIR in vivo. Adult porcine islets (APIs) or rat islets were implanted into the portal vein or under the renal subcapsular space of diabetic athymic mice. Graft survival and morphology were evaluated by measuring blood glucose levels and by performing immunohistochemical staining, respectively. Transplantation of rat islets, irrespective of implantation site, cured all diabetic athymic mice. APIs transplanted subcapsularly also cured all diabetic athymic mice, while none of the animals transplanted with an equivalent amount of APIs via the portal vein remained normoglycemic for more than 10 days after transplantation. Immunohistochemical staining on day 7 showed that most of intraportally transplanted APIs were entrapped in clots and infiltrated with CD11b+ leukocytes. Intraportal transplantation of APIs into athymic mice induced IBMIR, thus providing a small animal model for studying xenogeneic IBMIR.